According to a new report, published by KBV research, The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period.
The Cancer Treatment Centers segment is showcasing a CAGR of 18.2% during (2023 - 2030). Despite being smaller, cancer treatment centers offer more services than a standard doctor's office. For instance, a lot of cancer treatment centers offer medical services, including X-rays, MRIs, and various other imaging scans, lab work, blood tests, outpatient treatments, specialized care for certain medical disorders. They also perform routine physical exams, sutures for minor injuries, as well as radiation therapy or chemotherapy for cancer patients.
The Lymphoma segment is leading the Global T-Cell therapy Market by Indication in 2022 thereby, achieving a market value of $4.4 billion by 2030. Due to T-cell therapy's substantial success in treating blood malignancies like lymphoma, the segment is expanding. Furthermore, the growth is anticipated to be fueled by current cases as well as ongoing R&D in this field. According to the National Library of Medicine, nearly 3% of cancer diagnoses and fatalities worldwide are caused by non-Hodgins lymphoma (NHL), the most prevalent hematological malignancy.
The T-Cell Receptor (TCR)-Based segment has shown the growth rate of 21.4% during (2023 - 2030). The TCR-based adoptive treatment uses lymphocytes that have been genetically engineered to target particular tumor markers. Leukapheresis, lymphodepletion, creation of transduced TCR product, as well as infusion of TCR-based adoptive therapy are the steps that make up this structured and integrated treatment modality. The ability to treat a greater range of malignant diseases is enhanced by TCRs, thus driving the expansion of the segment.
The North America market dominated the Global T-Cell therapy Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3.3 billion by 2030. The Europe market is exhibiting a CAGR of 17.2% during (2023 - 2030). Additionally, The Asia Pacific market would showcase a CAGR of 18.5% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/t-cell-therapy-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
By End User
By Indication
By Therapy Type
By Geography
Companies Profiled
Unique Offerings 
